Common questions about Xeljanz (FAQ)
Q: What are the specific signs of a blood clot that require immediate attention while taking Xeljanz?
Regulatory documents state that symptoms associated with blood clots can include sudden shortness of breath or difficulty breathing, chest pain, swelling or tenderness in a leg or arm, or red or discolored skin on the affected limb. The potential for these conditions, such as pulmonary embolism or deep vein thrombosis, is documented in the safety information.
Q: Why does Xeljanz carry a Boxed Warning about certain serious health risks?
The FDA requires a Boxed Warning to highlight certain serious risks based on findings from clinical trials. This warning specifically calls attention to the documented risks of serious infections, Major Adverse Cardiovascular Events (MACE), malignancies (cancers), thrombosis (blood clots), and mortality.
Q: What are the most commonly reported side effects of Xeljanz?
According to the official product information, common side effects (those affecting up to 1 in 10 people) typically include upper respiratory tract infections, such as a cold or sinus infection, headache, diarrhea, and nasopharyngitis.
Q: Are there any specific heart-related risks associated with Xeljanz, particularly for older adults?
Official information indicates that patients who are ge 50 years of age and have at least one cardiovascular risk factor (such as a history of diabetes or coronary artery disease) have a documented increased risk of Major Adverse Cardiovascular Events (MACE), which includes heart attack and stroke.
Q: Is there an increased risk of certain types of cancer, such as lymphoma or skin cancer, with Xeljanz use?
Xeljanz is associated with an increased risk of certain cancers, including lymphoma and lung cancer, based on regulatory documents. Skin cancers have also been reported, particularly in current or past smokers.
Q: Does Xeljanz increase the risk of major cardiovascular events like heart attack or stroke?
Yes, official labeling highlights an increased risk of Major Adverse Cardiovascular Events (MACE), which encompasses non-fatal myocardial infarction (heart attack) and stroke. This risk is noted to be increased in patients aged 50 or older who have pre-existing cardiovascular risk factors.
Q: What are the symptoms of a serious allergic reaction to Xeljanz?
Serious allergic reactions are noted in the official label. Symptoms may include hives, rash, difficulty breathing, or swelling of the face, lips, tongue, or throat. These symptoms are listed in the product information as potentially requiring medical attention.
Q: Is it true that Xeljanz can cause shingles (Herpes Zoster)?
Yes, regulatory documents list Herpes Zoster (shingles) as a common adverse reaction, meaning it was observed to affect up to 1 in 10 people in clinical trials. Official safety information notes that patients may require monitoring for signs of this viral infection.
Q: Can Xeljanz affect cholesterol levels in the blood?
According to official product information, Xeljanz treatment is associated with dose-dependent increases in certain blood lipid levels. This includes elevations in total cholesterol, LDL cholesterol, and HDL cholesterol.
Q: Is hair loss a reported side effect of Xeljanz?
Hair loss (alopecia) has been reported in postmarketing surveillance and clinical literature, although it is not usually listed among the common adverse reactions in the primary regulatory tables. Postmarketing reports describe observations outside of controlled clinical trials.
Q: Can Xeljanz cause stomach or intestinal issues, such as perforation?
Yes, tears (perforations) in the stomach or intestines have been reported in clinical trials. Regulatory documents advise caution in patients with a history of diverticulitis or in those who are taking medications like NSAIDs or corticosteroids, which may also increase this risk.
Q: Are there any over-the-counter pain relievers that interact with Xeljanz?
The official regulatory label advises caution when Xeljanz is used at the same time as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. This is because the combination may potentially increase the risk of gastrointestinal perforation.
Q: Should I avoid certain supplements while on Xeljanz?
The regulatory label notes that all substances consumed should be discussed with a doctor. Some supplements, vitamins, and herbs, particularly those known to inhibit the CYP3A4 enzyme, may lead to increased levels of Xeljanz in the body.
Q: Is it necessary to avoid grapefruit or grapefruit juice while taking Xeljanz?
Yes, the official label and patient information indicate that grapefruit and grapefruit juice should be avoided during treatment with Xeljanz. This is because they can increase the blood level of the medication, which may lead to an increased risk of side effects.
Q: How long does it typically take for a person to notice the effects of Xeljanz?
Studies and official information indicate that for conditions like rheumatoid arthritis, most patients who respond to Xeljanz typically notice an improvement within the first 12 weeks of beginning treatment.
Q: Does Xeljanz need to be refrigerated, or how should it be stored?
Regulatory instructions state that both the tablets and the oral solution should be stored at Controlled Room Temperature (20 C to 25 C), which means they should not be refrigerated. The oral solution must be discarded 60 days after the bottle is first opened.
Q: Is Xeljanz a long-term treatment, or is it meant to be temporary?
Xeljanz is generally prescribed as a long-term treatment for chronic inflammatory conditions. Clinical trials, including long-term extension studies, have collected data on continuous use for several years.
Q: What is the role of Xeljanz in treating Ulcerative Colitis compared to other immune diseases?
For Ulcerative Colitis, Xeljanz is prescribed as a targeted oral therapy for moderately to severely active disease. Official dosing involves a higher initial induction dose to stabilize the condition, followed by a lower, long-term maintenance dose.
Q: Why must a doctor test for latent Tuberculosis (TB) before starting Xeljanz?
Screening for latent Tuberculosis (TB) is mandatory before and during Xeljanz therapy. This is because the drug's effect on the immune system may lower the body's ability to fight off infections, which could allow a latent (inactive) TB infection to become active.
Q: Can Xeljanz cause high blood pressure?
Yes, hypertension (high blood pressure) is listed in official regulatory documents as a common side effect of Xeljanz treatment, observed in clinical trials for conditions like rheumatoid arthritis.
Q: Is Xeljanz available in a form other than a tablet, such as an oral solution?
Yes, Xeljanz is available in three forms: an immediate-release tablet, an extended-release tablet (XR), and an oral solution. The oral solution is approved for use in pediatric patients based on their body weight.
Q: Is there a different risk profile for current or past smokers taking Xeljanz?
Yes, regulatory documents indicate that the risk of certain serious side effects, including Major Adverse Cardiovascular Events (MACE), cancers, and mortality, is further increased for current or past smokers compared to non-smokers.
Q: Why is monitoring blood cell counts important while taking Xeljanz?
Monitoring blood cell counts, specifically lymphocytes and neutrophils, is important because Xeljanz can cause these levels to decrease. Low counts are associated with an increased risk of serious infections, and official information requires therapy interruption if counts fall too low.
Q: What research has been done on the long-term effects of Xeljanz?
Long-term safety has been evaluated in open-label extension studies for conditions like rheumatoid arthritis. These studies provide data on the safety profile and sustained patterns of observed change for up to 8.5 years of continuous use, but they have inherent limitations.
Q: What is still uncertain about Xeljanz?
Official regulatory documents acknowledge that key areas of uncertainty include the long-term effects of the medication on all physiological systems. Additionally, comparative evidence showing how Xeljanz directly stacks up against all available treatments for certain indications remains a gap in the research.
Q: Are there specific dietary restrictions related to Xeljanz beyond grapefruit?
Official regulatory labels do not list any other specific food restrictions besides grapefruit, as Xeljanz may be taken with or without food. However, official product information notes that diet and concurrent substances are generally discussed with a specialist physician.
